ADPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Adaptive Biotechnologies's Cash Ratio for the quarter that ended in Dec. 2023 was 3.94.
Adaptive Biotechnologies has a Cash Ratio of 3.94. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Adaptive Biotechnologies's Cash Ratio or its related term are showing as below:
During the past 7 years, Adaptive Biotechnologies's highest Cash Ratio was 9.15. The lowest was 3.10. And the median was 6.54.
The historical data trend for Adaptive Biotechnologies's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Ratio | Get a 7-Day Free Trial | 7.37 | 6.54 | 3.10 | 4.54 | 3.94 |
Adaptive Biotechnologies Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Ratio | Get a 7-Day Free Trial | 4.54 | 4.89 | 4.38 | 3.98 | 3.94 |
For the Biotechnology subindustry, Adaptive Biotechnologies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Cash Ratio falls into.
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Adaptive Biotechnologies's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Ratio (A: Dec. 2023 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 346.401 | / | 88.015 | |
= | 3.94 |
Adaptive Biotechnologies's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:
Cash Ratio (Q: Dec. 2023 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 346.401 | / | 88.015 | |
= | 3.94 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (NAS:ADPT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Adaptive Biotechnologies's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kyle Piskel | officer: Principal Accounting Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Nitin Sood | officer: Chief Commercial Officer, MRD | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Tycho Peterson | officer: Chief Financial Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109 |
R Mark Adams | officer: Chief Operating Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Michelle Renee Griffin | director | 19723 NE 65TH LANE, KIRKLAND WA 98033 |
Stacy L Taylor | officer: SVP and General Counsel | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102 |
Leslie Trigg | director | C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112 |
Kevin T Conroy | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Robert Hershberg | director | 3005 FIRST AVENUE, SEATTLE WA 98121 |
Peter M Neupert | director | 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005 |
Sharon Benzeno | officer: Chief Commercial Ofc Imm Med | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Harlan S Robins | officer: Chief Scientific Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Francis Lo | officer: Chief People Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Michael J Pellini | director | 222 DUTTON MILL RD, WILLISTOWN PA 19380 |
Chad M Robins | director, officer: CEO and Chairman | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 12-10-2022
By sperokesalga sperokesalga • 04-12-2023
By sperokesalga sperokesalga • 05-24-2023
By PurpleRose PurpleRose • 07-12-2022
By Ds*** Ds*** • 09-02-2022
By Marketwired • 08-02-2023
By Tiesvg Tiesvg • 12-27-2022
By PurpleRose PurpleRose • 07-15-2022
By sperokesalga sperokesalga • 06-02-2023
By Marketwired • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.